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Patients with hemophilia present several unique challenges
in the management of atrial ﬁbrillation (AF), particularly
with regard to the use of anticoagulation and procedural risks
of thrombotic events. Here we describe a case of successful
AF ablation performed in a patient with hemophilia A.Case report
A 54-year-old man with mild to moderate hemophilia A,
obstructive sleep apnea on continuous positive airway
pressure, and paroxysmal AF was referred for AF catheter
ablation. Four years prior, he was evaluated for palpitations
and dyspnea. AF was conﬁrmed on ambulatory monitoring.
His CHA2DS2-VASc score was 0. He was trialed on a series
of antiarrhythmic medications including ﬂecainide, propafe-
none, dronedarone, dofetilide, and sotalol. In spite of these
medications, he continued to remain highly symptomatic
with paroxysms of AF initially lasting 6–9 hours at a time,
3–5 times a month but later increasing in frequency and
duration. He never required cardioversion.
Because of the unique comorbidity of hemophilia A, options
for management of his AF were carefully considered. This
included treatment with amiodarone, surgical ablation with left
atrial appendage ligation, and AF catheter ablation. In conjunc-
tion with his hematologist, the decision was made to pursue an
AF catheter ablation using the Arctic Front Advance Cryobal-
loon catheter (Medtronic Inc, Minneapolis, MN) with a standard
infusion protocol of a third-generation recombinant factor VIII.
He was well established with a primary hematologist for
his hemophilia with a baseline 5% factor activity level (mild-
moderate disease severity). With the use of standard factor
VIII replacement protocols, he had previously undergone
other procedures including an appendectomy. He had aKEYWORDS Atrial ﬁbrillation; Catheter ablation; Anticoagulation;
Hemophilia
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).history of experiencing spontaneous hemarthroses of periph-
eral joints, for which he received infusions of recombinant
factor VIII as needed.
On the morning of the ablation, a factor VIII assay
showed a baseline 13% activity level. He received 40 U/kg
of recombinant factor VIII per the protocol, which increased
the activity level to 131%. He was then brought to the
electrophysiology lab, where a transesophageal echocardio-
gram was performed demonstrating no left atrial thrombus.
The presenting rhythm was AF that spontaneously oscillated
between sinus rhythm and AF. Left and right femoral vein
access was obtained in the usual fashion using a modiﬁed
Seldinger technique. The left atrium was accessed with 2
separate transseptal punctures using Preface sheaths (Bio-
sense Webster, Diamond Bar, CA) with a BRK-1 transseptal
needle under intracardiac echocardiographic guidance.
Immediately after the ﬁrst transseptal, a heparin bolus was
administered followed by a heparin infusion with a goal
activated clotting time (ACT) in a lower target range between
250 and 300 seconds for this case (usual target range 300–
350 seconds at our institution). During the procedure, serial
ACTs were obtained to guide intraprocedural heparinization
to this goal. Actual ACTs varied between 190 and 283. The
ﬁrst Preface sheath was exchanged over a long J wire for a
12F FlexCath Steerable Sheath (Medtronic, Minneapolis,
MN), and a 28-mm Arctic Front Cryoablation balloon
catheter (Medtronic, Minneapolis, MN) was advanced into
the left atrium. Through the second Preface sheath, a ﬁxed 20
mm Lasso catheter (Biosense Webster, Diamond Bar, CA)
was used. Heparin was infused for a total of 1000 U/h
through both transseptal sheaths. A total of 3 4-minute freezes
in each of the left superior and left inferior pulmonary vein
antrums resulted in pulmonary vein isolation. Two 4-minute
freezes in the right superior pulmonary vein antrum resulted in
isolation. Phrenic nerve function was monitored by palpating
the abdomen during phrenic nerve pacing from the superior
vena cava. The right inferior pulmonary vein could not be
isolated using the cryoballoon owing to inability to achieve
adequate occlusion and poor contact. Therefore, the cryobal-
loon was exchanged for an externally irrigated radiofrequency
(RF) ablation catheter (3.5 mm Thermocool Navistar, Bio-
sense Webster). Antral isolation of the right inferior vein waspen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.06.007
KEY TEACHING POINTS
 The guideline recommendation for routine
anticoagulation around the time of catheter
ablation for atrial ﬁbrillation eliminates this
therapeutic option for many patients with bleeding
disorders. However, the evidence demonstrating
the need for such anticoagulation is based on
expert opinion and small observational studies and
lacks high-quality evidence to support its
necessity.
 Because standard factor replacement protocols
allow transient correction of the coagulation
cascade, patients with hemophilia may be able to
safely undergo catheter ablation for atrial
ﬁbrillation using intraprocedural heparin. However,
prolonged postprocedural anticoagulation is
contraindicated.
Heart Rhythm Case Reports, Vol 1, No 6, November 2015446successful with the RF catheter using multiple 25- to 30-watt
lesions. Entry and exit block was conﬁrmed in all 4 pulmonary
veins using the Lasso catheter. Isoproterenol challenge up to
20 microgram/min at the end of the case did not induce further
arrhythmias during the infusion and washout periods. At the
completion of the case, the patient was in sinus rhythm.
The catheters were removed and long sheaths exchanged for
short sheaths, which were then sutured in place and removed
later in recovery. Protamine was not administered.
The evening of and morning after completion of the case,
the patient received an additional 40 U/kg recombinant factor
VIII. Another factor VIII activity level was drawn the
morning after ablation that conﬁrmed continued deﬁciency
reversal with a measured activity level of 112%. No
postprocedural anticoagulation was used. He was observedR
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Figure 1 Proposed algorithm for management of antithrombotic therapy in pat
recommended unless the basal factor level is Z30%. Adapted from Mannucci etas an inpatient for 48 hours with no procedural complica-
tions. On discharge, he received 30 U/kg of recombinant
factor VIII daily for 7 days. No long-term antithrombotic
therapy was given. He was continued on sotalol for 2
months, at which point it was discontinued. In follow-up,
no late bleeding or thromboembolic complications had
occurred, including no hemarthroses. At 2 years of follow-up,
he had no clinical or documented recurrences of AF.Discussion
Hemophilia represents a related group of inherited and
acquired bleeding disorders, most commonly represented
by the X-linked recessive disorders hemophilia A (factor
VIII deﬁciency) and hemophilia B (factor IX deﬁciency).
No guidelines or randomized trials exist to guide the
management of patients with hemophilia and cardiovascular
comorbidities. Rather, expert consensus based on case
reports and observational data serve as the primary refer-
ences for clinicians.1,2 As the development and use of
recombinant factors has increased the life expectancy of
patients with hemophilia beyond 60–70 years of age, the
population at risk for developing AF has increased.2,3
Considerations must be made in the management of AF in
patients with hemophilia, including strategies for long-term
stroke reduction and procedural considerations.
Long-term stroke reduction in AF involves weighing the
stroke risk proﬁle (eg, CHA2DS2-VASc) vs the bleeding
risk. In the case of a patient with hemophilia, the bleeding
risk is dominant and warfarin is not recommended in patients
other than perhaps those with very mild hemophilia (native
factor activity levelZ30%). Algorithms have been proposed
to determine whether antithrombotic therapy is advisable
(Figure 1).2 If oral anticoagulation is prescribed, co-
treatment with factor infusion to an activity level goal of
30% could be considered, though has not been studiedia and Atrial Fibrillation 
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Figure 2 The coagulation cascade and primary targets of commonly used anticoagulants in the management of atrial ﬁbrillation and sites of deﬁciency in
patients with hemophilia A and B.
447Y. Lin et al Atrial Fibrillation in Patients with Hemophiliaextensively.3 Alternatives may become more widespread in
the future, including the use left atrial appendage occlusion
devices.4 It is unknown what role the direct oral antico-
agulants will have, if any, in patients with hemophilia and
AF. Figure 2 summarizes the main targets for commonly
used anticoagulants within the coagulation cascade.
For symptomatic patients, AF catheter ablation has
become an accepted option for maintenance of sinus rhythm,
particularly in patients who have failed an antiarrhythmic
medication.5,6 Both intraprocedural and postprocedural anti-
coagulation is felt to be critical to safe delivery of the
procedure. The 2014 ACC/AHA Guideline for the Manage-
ment of Patients With AF issued a class III recommendation
that “AF catheter ablation should not be performed in
patients who cannot be treated with anticoagulant therapy
during and after the procedure” based on consensus opinion
(level of evidence C).7 Similarly, the 2012 HRS/EHRA/
ECAS Expert Consensus Statement on Catheter and Surgical
Ablation of Atrial Fibrillation states that “systemic anti-
coagulation should be continued for at least 2 months
following an AF ablation procedure,” again based primarily
on expert opinion.5
In approaching AF ablation, anticoagulation is ﬁrst
required intraprocedurally. This requirement is based on
the risk of thrombus formation directly on the transseptal
sheaths, on the catheters in the left atrium, or at sites of
ablation. The latter is due to activation of the clotting cascade
at sites of endothelial disruption or due to char formation.
Expert consensus recommends intraprocedural anticoagula-
tion with heparin to ACT goals of 300–400 seconds.5 These
are largely based on studies performed before the introduc-
tion of the open-irrigated tip RF ablation catheter orcryoablation.7,8 More recently, published data have shown
that lower ACT goals of 225–250 seconds may be safe and
effective in the setting of externally irrigated ablation
catheters, single transseptal access, and relatively short
duration of left atrial ablation time.9,10 The optimal ACT
target range remains unknown and most centers continue to
have a goal of 300–350 seconds. The ACT relies on the
presence of a normal coagulation cascade, which is inher-
ently abnormal in the presence of a factor deﬁciency.11 In the
case of conditions such as hemophilia, exogenous factor
replacement can at least temporarily restore normal coagu-
lation. Therefore, the usual intraprocedural approach may
not need to be signiﬁcantly divergent and standard heparin
administration can be utilized. We chose to deliver heparin and
accepted a lower ACT target range in this patient knowing that
these variances were likely to be observed. Desmopressin is an
alternative to factor replacement, but it can have less predict-
able effects on the coagulation cascade and may have
prothrombotic effects through platelet activation.
The second phase of care requiring anticoagulation is in
the postprocedural period. In addition to the likelihood of
early recurrence of atrial arrhythmias, other theoretical
concerns include thrombus formation due to atrial stunning
or at sites of endocardial ablation and endothelial disruption.
Data supporting an early increased thromboembolic risk after
AF catheter ablation is based on observational data. Oral et al
published their experience with 7 thromboembolic events out
of 755 consecutive AF catheter ablations. All of the early
thromboembolic events after AF catheter ablation occurred
within the ﬁrst 2 weeks after ablation.12 The international
normalized ratio was documented to be subtherapeutic in 4
of 7 patients who had an early thromboembolic event (57%).
Heart Rhythm Case Reports, Vol 1, No 6, November 2015448Because the early thromboembolic events were unrelated to
the presenting rhythm or to baseline clinical variables, the
proposed mechanism was char and/or thrombus at sites of
left atrial endocardial ablation. However, all procedures in
this study utilized a solid-tip 8-mm-tip ablation catheter,
which is not commonly used with in modern AF ablation
procedures. It is likely that cryoablation or open irrigated
ablation catheters used most commonly today are less likely
to cause char and thrombus formation at endocardial ablation
sites than traditional RF catheters and reduce the risk of
stroke. The cryoballoon in particular was chosen in this case
because cryoablation has been shown to have diminished
risk of thrombosis owing to decreased activation of platelets
and the coagulation cascade and less vascular and endothe-
lial disruption.13
Only 1 study to date has been performed to explore
omitting anticoagulation after RF ablation for AF. Bunch
et al shared their center’s experience using aspirin alone
(rather than oral anticoagulation) following AF ablation.14
These 123 patients had a low baseline stroke risk (CHADS2
scores of 0–1) and an open irrigated RF ablation catheter was
used. There were no strokes or transient ischemic attacks in
patients treated with aspirin alone, raising the possibility that
warfarin is not needed in low-risk patients following AF
ablation procedures. We chose not to use any postprocedure
anticoagulation in our patient with hemophilia, given his
bleeding risk and low CHA2DS2-VASc score.
An alternative approach for patients with relative or
absolute contraindications to postprocedure anticoagulation
is surgical AF ablation. Consensus opinion is that anti-
coagulation should also be continued after surgical ablation
of AF for several months owing to the relatively high
incidence of early atrial arrhythmias following the proce-
dure.5 However, there is a paucity of evidence regarding the
optimal approach to periprocedural anticoagulation with
surgical AF ablation. Surgical ablation for AF offers the
theoretical advantage of surgical exclusion of the left atrial
appendage, although controversy exists regarding the true
beneﬁt of this for stroke reduction. Another advantage is that
the surgical approach, which is epicardial, avoids the need to
place catheters inside the left atrium and therefore perhaps
lowers the risk of thrombus formation.
We present a patient with hemophilia who successfully
underwent AF catheter ablation by using a standard factor
replacement protocol. To our knowledge, this is the ﬁrst
reported case of AF catheter ablation in a patient with
hemophilia. Other successful catheter-based procedures have
been reported in patients with hemophilia, though only 1 has
involved catheter ablation of an arrhythmia.15 In that case, a
child with hemophilia A underwent successful ablation of
atrioventricular nodal reentrant tachycardia with cryoabla-
tion. However, transseptal access was not required and no
long-term anticoagulation was recommended.
Though our patient’s baseline factor VIII level stratiﬁed
him into a lower severity of disease, his particular bleeding
risk was thought to be slightly higher in practice, as
evidenced by his history of peripheral hemarthroses.Moreover, his stroke risk was low, as estimated by a
CHA2DS2-VASc of 0. Because this is a single case report,
we cannot draw any conclusions as to the general safety of
this approach, including for those patients with a more severe
form of hemophilia or those with a higher CHA2DS2-
VASc score.Conclusion
AF catheter ablation involves both intraprocedural and
postprocedural anticoagulation, limiting this as a therapeutic
option for many patients with bleeding disorders such as
hemophilia who have symptomatic AF. In patients with a
low CHA2DS2-VASc score, an approach using a lower
intensity of intraprocedural anticoagulation and avoidance
of postprocedural anticoagulation may allow such patients to
safely undergo AF catheter ablation.References
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